CRDF Q4 2023 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$139M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$156,000+21.9% YoY

Gross Profit

$53,00034.0% margin

Operating Income

-$10M-6623.1% margin

Net Income

-$9M-5985.3% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+10.6%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$909,000

Balance Sheet

Total Assets

$82M

Total Liabilities

$12M

Stockholders' Equity

$70M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$156,000	$128,000	+21.9%
Gross Profit	$53,000	$128,000	-58.6%
Operating Income	-$10M	-$9M	-10.0%
Net Income	-$9M	-$9M	-7.4%